Literature DB >> 32631584

How to manage osteoporosis before the age of 50.

S Rozenberg1, O Bruyère2, P Bergmann3, E Cavalier4, E Gielen5, S Goemaere6, J M Kaufman7, B Lapauw8, M R Laurent9, J De Schepper10, J J Body11.   

Abstract

This narrative review discusses several aspects of the management of osteoporosis in patients under 50 years of age. Peak bone mass is genetically determined but can also be affected by lifestyle factors. Puberty constitutes a vulnerable period. Idiopathic osteoporosis is a rare, heterogeneous condition in young adults due in part to decreased osteoblast function and deficient bone acquisition. There are no evidence-based treatment recommendations. Drugs use can be proposed to elderly patients at very high risk. Diagnosis and management of osteoporosis in the young can be challenging, in particular in the absence of a manifest secondary cause. Young adults with low bone mineral density (BMD) do not necessarily have osteoporosis and it is important to avoid unnecessary treatment. A determination of BMD is recommended for premenopausal women who have had a fragility fracture or who have secondary causes of osteoporosis: secondary causes of excessive bone loss need to be excluded and treatment should be targeted. Adequate calcium, vitamin D, and a healthy lifestyle should be recommended. In the absence of fractures, conservative management is generally sufficient, but in rare cases, such as chemotherapy-induced osteoporosis, antiresorptive medication can be used. Osteoporosis in young men is most often of secondary origin and hypogonadism is a major cause; testosterone replacement therapy will improve BMD in these patients. Diabetes is characterized by major alterations in bone quality, implying that medical therapy should be started sooner than for other causes of osteoporosis. Primary hyperparathyroidism, hyperthyroidism, Cushing's syndrome and growth hormone deficiency or excess affect cortical bone more often than trabecular bone.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diagnosis; Osteoporosis; Review; Screening; Treatment

Year:  2020        PMID: 32631584     DOI: 10.1016/j.maturitas.2020.05.004

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  13 in total

Review 1.  Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.

Authors:  Michaël R Laurent; Stefan Goemaere; Charlotte Verroken; Pierre Bergmann; Jean-Jacques Body; Olivier Bruyère; Etienne Cavalier; Serge Rozenberg; Bruno Lapauw; Evelien Gielen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

2.  Blood Lead Level Is Negatively Associated With Bone Mineral Density in U.S. Children and Adolescents Aged 8-19 Years.

Authors:  Aiyong Cui; Peilun Xiao; Baoliang Hu; Yuzhuo Ma; Zhiqiang Fan; Hu Wang; Fengjin Zhou; Yan Zhuang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-01       Impact factor: 6.055

3.  Therapeutic effect of Shinkiwhan, herbal medicine, regulates OPG/RANKL/RANK system on ovariectomy-induced bone loss rat.

Authors:  Il-Bok Seo; Kang Pa Lee; Sun-Young Park; Sang-Hyun Ahn
Journal:  Phys Act Nutr       Date:  2020-09-30

Review 4.  Anorexia nervosa: COVID-19 pandemic period (Review).

Authors:  Mihai Cristian Dumitrașcu; Florica Șandru; Mara Carsote; Razvan Cosmin Petca; Ancuta Augustina Gheorghisan-Galateanu; Aida Petca; Ana Valea
Journal:  Exp Ther Med       Date:  2021-05-26       Impact factor: 2.447

5.  Reference values for bone density and bone mineral content from 5 to 80 years old in a province of Chile.

Authors:  Marco Cossio-Bolanos; Rossana Gomez-Campos; Rubén Vidal-Espinoza; Jose Fuentes-Lopez; Luis Felipe Castelli Correia de Campos; Cynthia Lee Andruske; Camilo Urra-Albornoz; Fernando Alvear Vasquez
Journal:  PeerJ       Date:  2022-03-23       Impact factor: 2.984

6.  Mechanism and Experimental Verification of Luteolin for the Treatment of Osteoporosis Based on Network Pharmacology.

Authors:  Guihong Liang; Jinlong Zhao; Yaoxing Dou; Yuan Yang; Di Zhao; Zhanpeng Zhou; Rui Zhang; Weiyi Yang; Lingfeng Zeng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-08       Impact factor: 6.055

7.  Prediction model for the risk of osteoporosis incorporating factors of disease history and living habits in physical examination of population in Chongqing, Southwest China: based on artificial neural network.

Authors:  Yuqi Wang; Liangxu Wang; Yanli Sun; Miao Wu; Yingjie Ma; Lingping Yang; Chun Meng; Li Zhong; Mohammad Arman Hossain; Bin Peng
Journal:  BMC Public Health       Date:  2021-05-26       Impact factor: 3.295

Review 8.  The Role of Osteoclast Energy Metabolism in the Occurrence and Development of Osteoporosis.

Authors:  Wacili Da; Lin Tao; Yue Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-12       Impact factor: 5.555

9.  Assessment of Low Bone Mineral Density in Untreated Patients with Takayasu's Arteritis.

Authors:  Lingfei Mo; Jing Wang; BoMiao Ju; Yanhua Wang; Jing Luo; Juan Tian; Lan He
Journal:  Biomed Res Int       Date:  2021-10-13       Impact factor: 3.411

10.  Association between hypertriglyceridemic waist phenotype and hypogonadism in Taiwanese adult men.

Authors:  Sheng-Kuang Wang; Meng-Chih Lee; Chia-Lien Hung; Hsin-Hung Chen; Chun-Cheng Liao; Yu-Lung Chiu
Journal:  PLoS One       Date:  2022-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.